Audentes Therapeutics, Inc. (BOLD) Financial Statements (2023 and Earlier)

Company Profile

Business Address 600 CALIFORNIA ST., 17TH FLOOR
SAN FRANCISCO, CA 94108
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments414,307133,605104,883
Cash and cash equivalents144,34938,96736,359
Short-term investments269,95894,63868,524
Restricted cash and investments 90730
Other undisclosed current assets5,4653,3152,824
Total current assets:419,772137,010108,437
Noncurrent Assets
Property, plant and equipment32,09924,37218,936
Intangible assets, net (including goodwill)11,63111,63111,631
Goodwill3,6313,6313,631
Intangible assets, net (excluding goodwill)8,0008,0008,000
Restricted cash and investments3,7483,6043,020
Other noncurrent assets5,3052,04533
Total noncurrent assets:52,78341,65233,620
TOTAL ASSETS:472,555178,662142,057
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21,05112,68512,295
Accounts payable8,1233,8532,424
Accrued liabilities12,9288,8329,871
Deferred rent credit456
Business combination, contingent consideration, liability2,3454,643 
Deferred revenue and credits384265
Total current liabilities:23,85217,71212,560
Noncurrent Liabilities
Liabilities, other than long-term debt5,9498,93510,126
Deferred revenue and credits2,5351,777
Deferred rent credit4,720
Asset retirement obligations215743709
Deferred tax liabilities, net1,0141,0143,260
Business combination, contingent consideration, liability 4,6434,380
Other undisclosed noncurrent liabilities (4,583) 
Total noncurrent liabilities:5,9494,35210,126
Total liabilities:29,80122,06422,686
Stockholders' equity
Stockholders' equity attributable to parent442,754156,598119,371
Additional paid in capital762,284347,327219,811
Accumulated other comprehensive loss(60)(80)(29)
Accumulated deficit(319,470)(190,649)(100,411)
Total stockholders' equity:442,754156,598119,371
TOTAL LIABILITIES AND EQUITY:472,555178,662142,057

Income Statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
Operating expenses(134,372)(93,177)(60,046)
Operating loss:(134,372)(93,177)(60,046)
Nonoperating income5,551693378
Investment income, nonoperating6,030767472
Other nonoperating expense(479)(74)(94)
Loss from continuing operations before income taxes:(128,821)(92,484)(59,668)
Income tax benefit 2,246 
Net loss available to common stockholders, diluted:(128,821)(90,238)(59,668)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
Net loss:(128,821)(90,238)(59,668)
Other comprehensive loss  (19)
Comprehensive loss:(128,821)(90,238)(59,687)
Other undisclosed comprehensive loss, net of tax, attributable to parent(60)(51) 
Comprehensive loss, net of tax, attributable to parent:(128,881)(90,289)(59,687)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: